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Glioblastoma (GBM) is the most frequent and aggressive primary tumor of the brain and
averages a life expectancy in diagnosed patients of only 15 months. Hence, more effective
therapies against this malignancy are urgently needed. Several diseases, including cancer, are
featured by high levels of reactive oxygen species (ROS), which are possible GBM hallmarks
to target or benefit from. Therefore, the covalent linkage of drugs to ROS-responsive
molecules can be exploited aiming for a selective drug release within relevant pathological
environments. In this work, we designed a new ROS-responsive prodrug by using Melphalan
(MPH) covalently coupled with methoxy polyethylene glycol (mPEG) through a ROS-cleavable
group thioketal (TK), demonstrating the capacity to self-assembly into nanosized micelles. Full
chemical-physical characterization was conducted on the polymeric-prodrug and proper
controls, along with in vitro cytotoxicity assayed on different GBM cell lines and “healthy”
astrocyte cells confirming the absence of any cytotoxicity of the prodrug on healthy cells (i.e.
astrocytes). These results were compared with the non-ROS responsive counterpart,
underlining the anti-tumoral activity of ROS-responsive compared to the non-ROS-
responsive prodrug on GBM cells expressing high levels of ROS. On the other hand, the
combination treatment with this ROS-responsive prodrug and X-ray irradiation on human
GBM cells resulted in an increase of the antitumoral effect, and this might be connected to
radiotherapy. Hence, these results represent a starting point for a rationale design of
innovative and tailored ROS-responsive prodrugs to be used in GBM therapy and in
combination with radiotherapy.
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Cancer represents one of the most lethal diseases worldwide
(Kim et al., 2014), and in high-income countries, the number of
cancer deaths is currently double the deaths caused by
cardiovascular disease (CVD) (Mahase, 2019). Among all
deadly types of cancer, brain cancer is one of the most difficult
to treat and cure (Lee et al., 2013). In particular, glioblastoma
(GBM) malignant grade IV astrocytic tumor (Resende et al.,
2018) is the most frequent and aggressive primary tumor with
the poorest prognosis (Tsai et al., 2012; Gramatzki et al., 2013;
Lee et al., 2013; Legendre et al., 2016; Yang et al., 2016) with a
median survival time of only 15 months (Majewska et al., 2017).
Due to the ability of GBM cells to migrate to other brain regions,
after diagnosis and initial treatment, GBM recurrence takes place
within 6–12 months after diagnosis (Tsai et al., 2012; Lee et al.,
2013; Yang et al., 2016) as a secondary tumor, which is one of the
main reasons that account for the lethality of GBM (Haar
et al., 2012).
Standard GBM therapy consists of tumor surgery followed by
concomitant radio- and chemotherapy with temozolomide
(TMZ) (Majewska et al., 2017; Resende et al., 2018), one of the
few chemotherapeutic agents with an acceptable blood-brain
barrier (BBB) penetration (20% of the injected dose). Apart from
TMZ, carmustine, and lomustine are the most widely used drugs
for GBM treatment (Tseng et al., 2015). Nevertheless, lomustineFrontiers in Pharmacology | www.frontiersin.org 2shows a brain/plasma ratio of 20% in rats, which is lower
compared to TMZ, with 22–41%. Regarding carmustine, its
passage through the BBB is lower with higher CNS toxicity
(Wang et al., 2019a). Bevacizumab is used in patients that do not
respond to TMZ, but its poor BBB crossing leads to high
concentrations being administered and, consequently, to
adverse effects (Sousa et al., 2019).
Nevertheless, standard therapy with TMZ only increases
survival for 2.5 months (Resende et al., 2018). This is probably
due to the aggressiveness of recurrent tumors, the antitumoral
drug resistance frequently observed (Raucher et al., 2018), and
the often low selectivity of chemotherapeutics (Hagen et al.,
2012), with frequent administrations (Farokhzad and Langer,
2006) leading to decreased patient compliance and increase in
drug resistance (Yang et al., 2016). Hence, the design of new
therapies against GBM that prolong survival or cure the disease
are strongly needed.
Drug Delivery Systems (DDS) that improve residence time in
circulation, solubility, and targetability of chemotherapeutic
drugs were applied for some products on the market such as
Abraxane®, Doxil®, Onivyde®, and Zoladex® that are already
approved for their clinical use in cancer treatment (Farokhzad
and Langer, 2006; Liu et al., 2016; Gonda et al., 2019).
Nowadays, cancer therapy strategies are aiming to be more
personalized due to the presence of tumor heterogeneity among
cancer patients (Meel et al., 2019) leading to a possible inefficacyGRAPHICAL ABSTRACT |May 2020 | Volume 11 | Article 574
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DDS for the treatment of cancer, it is necessary to develop more
precise nanomedicines that take into consideration tumor
biology and peculiar pathological features (Gonda et al., 2019).
In this regard, a DDS with the possibility to sense the tumor
environment for a more selective drug release (Cobo et al., 2015)
holds great promise when it comes to advances in the
development of so-called “Smart” DDS.
Aiming at drug release in a given pathological condition is
highly sought after (Najer et al., 2015; Duskey et al., 2017; Rigon
et al., 2019; Tosi et al., 2019), and “Smart” DDS that are sensitive
to a specific stimulus (such as pH, enzymes, glucose, GSH, and
ROS) are currently being designed for their application against
several diseases, including cancer (Kwon et al., 2015; Liu et al.,
2016), with some relevant preclinical outcomes in terms of
efficacy (Sun et al., 2017).
Oxidative stress, produced by a disequilibrium between ROS
generation and detoxification (Sharma et al., 2007) is a common
feature of numerous pathologies, and is promoted by high
metabolic demand, oncogenic stimulation, and mitochondrial
dysfunction (Pelicano et al., 2004). In inflammatory diseases, the
activated leukocytes produce both inflammatory mediators and
ROS. Thus, inflammatory diseases are generally characterized by
ROS overload (Lu et al., 2017). Similarly in neurodegenerative
diseases such as Huntington’s disease, Alzheimer’s disease, and
Parkinson’s disease, high oxidative stress is featured (Wang et al.,
2015). Therefore, the design of ROS-responsive prodrugs can
also improve the selectivity and efficiency of drugs that are
applied in these diseases. TK-based ROS-responsive DDS
against inflammatory conditions such as inflammatory bowel
disease (IBD) (Li et al., 2019) have already been developed and
demonstrated to minimize ROS-triggered tissue damage.
However, to our knowledge, neither ROS-responsive DDS nor
prodrugs against neurological diseases have been designed
applying TK-technology so far.
Interestingly, the continuous production of ROS (hydroxyl
radical, H2O2, and superoxide) by GBM cells is needed for the
cells’ growth (Li et al., 2016; Hwang et al., 2018), and the design
of DDS that trigger the release of anticancer drugs upon ROS
stimulus (known as ROS-responsive DDS) could significantly
improve the effectivity of chemotherapeutic agents in GBM as
confirmed by a number of studies on ROS-responsive polymeric
prodrugs in cancer therapy (Yue et al., 2016; Xu et al., 2017; Pei
et al., 2019; Wang et al., 2019b). A plethora of ROS-responsive
chemical groups have been developed, for example:
polypropylene sulfide, selenium and tellurium, polyoxalate,
poly(proline), phenyl boronic ester, and more recently
thioketal (TK) were used as linkers for the synthesis of ROS-
responsive systems.
Among anticancer drugs, Melphalan (MPH), an alkylating
molecule, currently used for the treatment of myeloma, ovarian
cancer, breast cancer, neuroblastoma, regionally advanced
malignant melanoma, and localized soft tissue carcinoma
(Colvin, 2003; Ajazuddin et al., 2013), was inserted into some
GBM treatment regimens (Bottom et al., 2000; Gahramanov
et al., 2014). Like TMZ, MPH crosses the BBB and is readilyFrontiers in Pharmacology | www.frontiersin.org 3taken up by cancer cells making it a good candidate against GBM
(Colvin, 2003); however, its poor water solubility (0.1 µg/ml, 25°C)
(Ajazuddin et al., 2013) and its non-tumor selectivity represent
important drawbacks of its use.
To overcome chemical-physical limitations (i.e., poor
solubility) and to increase loco regional and site-specific
activity, several strategies are already known and could be
exploited. To improve the solubility of chemotherapeutic
agents, the conjugation of chemotherapeutic drugs with
polyethylene glycol (PEG), known as PEGylation, has a long
history with already established strategies present in clinical
setting. Beyond the advantage of increasing circulation kinetics
by extending residence time in the blood and human safety,
(Swierczewska et al., 2015), administrating PEGylated cytotoxic
drugs instead of the free drugs could lead to the possibility of by-
passing drug efflux, mediated by P-glycoproteins (P-gps). P-gps
are one of main reasons for the limited efficacy of
chemotherapeutic drugs in GBM, being responsible for efflux
events of cytotoxic drugs from the cancer cells (Kirtane et al.,
2013) and even at the BBB level. This favorable feature is
particularly needed in the case of MPH, with an in vivo a
circulation half-life of only 75 min (Kuczma et al., 2016).
Furthering this technology by creating a prodrug which is
activated as a consequence of a pathological stimulus to improve
locoregional and site-specific delivery could be an intelligent
approach and has been widely reviewed (Weidle et al., 2014;
Taresco et al., 2018; Zeng et al., 2018) and investigated for GBM
treatment (Taresco et al., 2018). The innovation would consist of
inserting a linker between PEG and a drug that responds to a
pathologic stimulus, thus improving the selectivity as well as the
effectivity of the drug (Chang et al., 2016). TK linkers are
biocompatible linkers which are degraded to thiol-containing
groups upon exposure to the most relevant ROS (hydroxyl
radical, H2O2, and superoxide) (Shim and Xia, 2013; El‐Mohtadi
et al., 2019), and have been recently used in the design of ROS-
responsive DDS for the delivery of drugs, siRNA, and DNA in
cancer and inflammatory diseases. To our knowledge, TK-based
ROS-responsive DDS for the treatment of GBM have not been
previously developed (Lee et al., 2013; Zheng et al. 2019).
Moreover, few examples of the use of ROS-responsive delivery
systems for GBM treatment are reported in the literature, such as,
phenyl boronic ester groups (as the ROS-responsive unit) and
angiopep-2 peptide (BBB-targeting ligand), for the delivery of
siRNA to silence PLK1 and VEGFR2 (Zheng et al., 2019).
Previously, proof-of-concept studies used the biocompatible
(mPEG-TK-COOH) (Swierczewska et al., 2015; Regmi et al.,
2019) to create an ROS-responsive mPEG-TK conjugate with a
fluorescent model drug (Cy5), and demonstrated a stimulus-
responsive release of this dye only in brain cancer cells (C6 rat
GBM cells) and not in healthy brain cells (rat astrocytes)
(Oddone et al., 2019). Based on these results, in this study, we
propose to exploit mPEG-TK-COOH polymer, to produce a
ROS-responsive antitumor prodrug with MPH, namely mPEG-
TK-MPH, for the selective MPH release in GBM cells.
To that end, a physical-chemical characterization as well as in
vitro efficacy and cytotoxicity studies were performed. Also,May 2020 | Volume 11 | Article 574
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and radiation treatment (which could induce ROS production)
the potential synergistic effects between the ROS-responsive
mPEG-TK-MPH prodrug and X-ray irradiation were explored
using rat and human GBM cells in combinatory treatment
regimens (Yamamori et al., 2012). These positive results
combining the biocompatible mPEG-TK-COOH with MPH to
form mPEG-TK-MPH shows great promise in the ability to
selectively target GBM cells due to its high ROS levels. This will
greatly increase the possibility to further therapeutic options
against such a deadly disease. Furthermore, these DDS will
readily translate to treatment possibilities for numerous other
diseases characterized by high ROS such as inflammatory or
neurodegenerative diseases.MATERIALS AND METHODS
Materials
Methoxy-polyethylene glycol amine (mPEG-NH2, Mw 5.000 Da)
and mPEG propionic acid (Mw 5.000 Da) were purchased from
JenKem Technology and Sigma-Aldrich, respectively. N-
hydroxy succinimide (NHS) and N-(3-dimethylaminopropyl)
-N-ethyl carbodiimide hydrochloride (EDC. HCl) were
obtained from Sigma-Aldrich and used directly. All solvents
used, 3-mercaptopropionic acid (3-MPA), dichloromethane
(DCM), dimethylformamide (DMF), acetone, hydrogen
peroxide (H2O2), hexane, and methanol were of analytical
grade and used without further purification. Melphalan was
purchased from Fisher Scientific (Milano, Italy). Ultrapure
water, which was used for all the experiments, was provided by
a Milli-Q water system (Millipore, Bedford, MA, USA). F12-K
and trypsin (TrypLE Select Enzyme [1X]) were purchased from
Gibco. Fetal bovine serum (FBS), penicillin-streptomycin,
oxidative fluorescent dye, and dihydroethidium (DHE), were
purchased from Sigma-Aldrich. DPBS and DMEMHigh Glucose
were purchased from Lonza (Verviers, Belgium).Frontiers in Pharmacology | www.frontiersin.org 4Synthesis
Synthesis of TK Containing Linker (TK-C.L.) and
ROS-Responsive mPEG-TK-COOH Polymer
The synthesis of TK-C.L. and mPEG-TK-COOH polymer was
performed according to our previous article, without
modifications (Oddone et al., 2019). For the synthesis of
TK.C.L., a mixture of 3-MPA (49.1 mmol) and anhydrous
acetone (98.2 mmol) was stirred for 4 h in HCl (g)
atmosphere. The reaction was stopped by placing the mixture
on an ice salt bath, and the product was obtained after several
washes with hexane and cold water. The product was then
characterized by 1H NMR and ESI-MS (Figure S1A). For the
synthesis of mPEG-TK-COOH polymer, the following
compounds were dissolved in DCM and stirred for 48 h at
ambient temperature: mPEG-NH2 5.000 Da (0.1 mmol), TK-
C.L. (1 mmol), EDC. HCl (1.2 mmol), and NHS (1.2 mmol). The
product was precipitated with diethyl ether, and after solvent
elimination, it was dissolved in a minimal DMF volume and
purified by dialysis (MWCO: 3.500 Da) against MilliQ water for
72 h. After dialysis, the product inside the dialysis bag was freeze-
dried, and the white powder obtained was characterized by 1H
NMR and Bruker Ultraflextreme MALDI-TOF MS/MS (Bruker
Daltonics, Bremen, Germany) (Figure S1B).
Synthesis of ROS-Responsive mPEG-TK-MPH and
Non-ROS Responsive mPEG-MPH (Control)
Prodrugs
The terminal carboxylic acid group on mPEG-TK-COOH or
mPEG propionic acid (used as control) polymers (6 mmol), were
activated with EDC.HCl (60 mmol) and NHS (60 mmol) for 1.5 h
in a DMF/DMSO (1:1 v/v) solvent mix. Right after the activation,
the reaction was initiated with the addition of MPH (30 mmol) to
the mixture and left stirring up to 48 h at 35°C (Schemes 1A, B).
The reaction was stopped, and the mix dialyzed (MWCO: 3.500
Da) against methanol for 48 h and finally against Milli Q water
for an additional 24-h period. At the end of the purification
process, the prodrugs were freeze-dried and kept in a desiccatorA
B
SCHEME 1 | Syntheses of prodrug with MPH. (A) mPEG-TK-MPH. (B) mPEG-MPH prodrug synthesis.May 2020 | Volume 11 | Article 574
Oddone et al. Responsive Polymeric Prodrug Against Glioblastomauntil use. The prodrugs were characterized by 1H NMR and
MALDI-TOF.
Self-Assembly in Water
Either mPEG-TK-MPH or mPEG-MPH prodrugs suspensions
in MilliQ water were prepared (0,1–10 mg/ml concentration
range). Briefly, an exact amount (10 mg) of either of the prodrugs
or their respective precursor polymers (mPEG-TK-COOH and
mPEG-P.A., respectively), was suspended in 1 ml of MilliQ
water. Then, different prodrug or polymer suspension
concentrations were prepared by serial dilutions in MilliQ
water for self-assembly ability studies and analyzed by photon
correlation spectroscopy (PCS) using Zetasizer Nano ZS
(Malvern, UK) and AFM measurements.
Characterization
1H NMR, ESI-MS, and MALDI-TOF
1H NMR spectra of TK-C.L. and mPEG-TK-COOH polymer
were acquired on Bruker Avance400 NMR (Bruker Biospin,
Rheinstetten, Germany) in CDCl3. In the case of mPEG-TK-
MPH and mPEG-MPH prodrugs, the 1H NMR spectra were also
acquired on Avance400-Bruker spectrometer in CD3OD. For all
1H NMR spectra, tetramethylsilane (TMS) was used as an
internal standard. The identification of all proton signals in
mPEG-TK-MPH and mPEG-MPH was completed after 1D
and 2D (COSY) 1H NMR analyses.
TK-C.L. mass spectra were acquired with Q-TOF Accurate-
Mass G6520A—Agilent Technologies, from which an ESI-MS
spectrum in negative mode was obtained. Mass spectra of
mPEG-TK-COOH, mPEG-TK-MPH, and mPEG-MPH were
acquired with a Bruker Ultraflex TOF/TOF, MALDI-TOF/TOF
mass spectrometer.
Size and Morphology of Self-Assembled Prodrugs
The mean particle size (Z-average) and the polydispersity index
(PDI) of self-assembled prodrug micelles at different prodrug
concentrations (10–0.01 mg/ml range) were determined through
PCS using a Zetasizer Nano ZS (Malvern, UK; Laser 4 mW He–
Ne, 633 nm, laser attenuator automatic, transmission 100–
0.0003%, detector avalanche photodiode, Q.E. > 50% at 633
nm) at room temperature. A 10 mg/ml suspension of either of
the prodrugs in Milli-Q water was prepared and directly
measured. Then, serial dilutions from these prodrug
suspensions were prepared and immediately measured after
vortex mixing. All measurements were carried out in triplicate.
Atomic force microscopy (AFM) was used to analyze the
morphology of self-assembled prodrugs. A selected sample of
mPEG-TK-MPH suspended at a concentration of 0.7 mg/ml,
was selected to be observed through Atomic Force Microscope
(Park Instruments, Sunnyvale, CA, USA), at about 20°C
operating in air and in non-contact (NC) mode using a
commercial silicon tip-cantilever (high resolution noncontact
“GOLDEN” Silicon Canti-levers NSG-11, NT-MDT, tip
diameter 5–10 nm; Zelenograd, Moscow, Russia) with stiffness
about 40 Nm−1 and a resonance frequency around 150 kHz.
Briefly, mPEG-TK-MPH dispersed in water at a selected
concentration of 0.7 mg/ml, was deposited onto mica surfaceFrontiers in Pharmacology | www.frontiersin.org 5on a freshly cleaved mica disk (1 cm x 1 cm); 2 min after the
deposition, the water excess was removed using blotting paper.
The AFM topographical image, representing the amplitude of
the vibrations of the cantilever, was obtained with a scan rate of 1
Hz and processed using a ProScan Data Acquisition software.
MPH Content on mPEG-TK-MPH and
mPEG-MPH Prodrugs
MPH content on the prodrugs was expressed as µg of MPH per mg
of prodrug and was determined by measuring the absorbance of
prodrugs solutions in methanol. The measurement was performed
on a spectrophotometer at l= 300 nm (the maximum absorbance
wavelength we obtained with MPH andMPH prodrugs). TheMPH
content of either of the prodrugs was calculated based on a
calibration curve of pure MPH in methanol (linearity in the range
between 11.58–74.25 µg/ml; r2 = 0.998950).
In Vitro Studies of mPEG-TK-MPH and
mPEG-MPH on Astrocytes (Control) Cells
and GBM Cells
Cell Culture
All cell lines were from ATCC (American Type Culture
Collection). C6 Rat GBM cells were cultured in F-12 k medium
supplemented with 20% FBS and 1% penicillin/streptomycin.
Purified newborn rat DI TNC1 primary astrocytes were obtained
by the mechanical dissociation method from cultures of cerebral
cortex as originally described (McCarthy and de Vellis, 1980). DI
TNC1 Rat Astrocyte cells and human GBM cells (U87MG and
U251MG cells) were cultured in DMEM High Glucose medium
supplemented with 10% FBS and 1% penicillin/streptomycin. All
cell lines were maintained in a humidified incubator at 37°C and
5% CO2.
Determination of the Levels of ROS in Rat GBM and
Astrocytes Cells
C6 and DI TNC1 cells were seeded (100,000 cells/ml) on poly-L-
lysine (0.1 mg/ml; Sigma-Aldrich) coated glass coverslips in a 24
well plate and incubated at 37°C until 80% confluency was
reached. Then, the cells were rinsed with 1X PBS and fixed
with 4% paraformaldehyde solution (PFA) in 1X PBS. Cell nuclei
were counterstained with DAPI, and coverslips subsequently
mounted using Vecta Mount (Vector Laboratories, USA). The
cells were observed using a confocal laser-scanning microscope
(Zeiss LSM710). CellROX fluorescence of confocal images of C6
and DI TNC1 cells was quantified using ImageJ (National
Institutes of Health), by measuring at least 20 cells per
condition and cell line.
Cytotoxicity Studies of ROS-Responsive and
Non-ROS-Responsive Prodrugs on C6 GBM and
DI TNC1 Astrocytes Cells
The cytotoxicity of mPEG-TK-MPH and mPEG-MPH prodrugs
on C6 cells was evaluated by acquiring cell index vs. time data in
real-time, using the xCELLigence RTCA MP instrument (ACEA
Biosciences). The experiments were carried out on 16 well E-
Plates (ACEA Biosciences), which were coated with poly-l-lysineMay 2020 | Volume 11 | Article 574
Oddone et al. Responsive Polymeric Prodrug Against Glioblastoma(PLL). After coating, plates were seeded with C6 or DI TNC1
cells (2 x 104 cells/ml) and put into xCELLigence RTCA MP
instrument station, where cell index vs. time curves were
recorded. After 24 h of cell seeding, the plates were removed
from the instrument, the culture medium was renewed, and cells
treated with mPEG-TK-MPH and mPEG-MPH prodrugs at an
equivalent concentration of MPH of 11 µM (reported MPH IC50
on C6 cells at 48 h of treatment (Kupczyk-Subotkowska et al.,
1997)). Cells were also treated with free MPH and mPEG-TK-
COOH (control). Immediately after the addition of the
compounds, the plates were put back into XCELLigence
station, and the cell index was measured every 5 min up to 48
h. At the end of the experiment, the data were analyzed using the
RTCA Data Analysis Software 1.0. The cell index of all treated
groups and control groups were normalized to 1 at the time point
where the treatment started; normalized cell index vs. time
curves were considered for data analysis.
Determination of the Levels of ROS in Human GBM
Cells
U87 MG and U251 MG cells were grown on glass slides (Ibidi,
Martinsried, Germany) by plating at a density of 5 x 104 cells/ml.
After 48 h of incubation, the cells were washed with PBS and
immediately incubated with DHE fluorescent dye in PBS (5 mM)
for 30 min at 37°C. Cells were then washed with PBS and fixed
with PFA (4%) for 15 min. The cells were washed with PBS and
kept at 4°C until analysis. The cells were observed using a
confocal microscope (Zeiss LSM700), and the images obtained
were analyzed by Image J. The quantification was performed by
measuring the fluorescence of 10 ROI per image in triplicate.
Channels used: DAPI (405 nm) and EthD (555 nm).
Cytotoxicity Studies of ROS-Responsive and Non-
ROS-Responsive Prodrugs on Human GBM Cells
U87 MG and U251 MG cells were seeded on 96 well plates at a
density of 5 x 104 cells/ml and kept in an incubator at 37°C for 24
h. The medium was replaced, and cells were treated with mPEG-
TK-MPH and mPEG-MPH prodrugs, at equivalent
concentrations of MPH (concentration range: 10–1,000 µM) as
well as free MPH. After 48 h of treatment, the medium was
removed, the cells were washed with DPBS and then incubated
for 3 h at 37°C in culture medium containing Resazurin (44 mM).
Finally, the fluorescence was measured on a plate reader
(CLARIOstar) at lexc= 545 nm/lem= 600 nm. Relative cell
viability was expressed as a percent where 100% was set based on
the non-treated control cells.
Influence of X-Ray Irradiation on ROS-Responsive
and Non-ROS-Responsive Prodrugs Cytotoxicity on
Human GBM Cells
U87 MG and U251 MG cells were seeded in 96 well plates at a
density of 5 x 104 cells/ml. After 24 h of incubation, the cells were
irradiated with X-ray (Edimex Faxitron) at the dose of 4 Gy.
Immediately after being irradiated, cells were treated with free
MPH (1,000 µM), mPEG-TK-MPH, and mPEG-MPH prodrugsFrontiers in Pharmacology | www.frontiersin.org 6at an equivalent concentration of 1,000 µM. After 24 h, a second
irradiation round (4 Gy dose) was applied to the cell plates.
Finally, at the end of the experiment (48 h counted from the first
irradiation dose), the cell viability of cells was indirectly
measured again by the resazurin method (described in
section 2.5.5).
Statistics
All data are shown as the mean of at least three experiments ±
SD. GraphPad Prism 5 was used for statistical analyses. For
pairwise comparisons, unpaired t-test, one-way, and two-way
ANOVA with Bonferroni post-hoc test analysis were performed.RESULTS AND DISCUSSION
mPEG-TK-MPH and mPEG-MPH Synthesis
and Characterization
Both prodrugs (mPEG-TK-MPH and control mPEG-MPH)
(Schemes 1A, B) were obtained as a pale-yellow powder, with
product yields over 90% (94 and 93%, respectively). The absence
of free MPH, and thus the purity of both prodrugs was confirmed
by RP-HPLC (data not shown). The MPH content of mPEG-TK-
MPH andmPEG-MPH prodrugs was 56.3 ± 1.1 mg/mg and 63.6 ±
4.9 mg/mg, respectively.
1H NMR spectra of either of the prodrugs show the presence
of chemical shifts ascribed to protons pertaining to the benzenic
group of MPH (6.69 and 7.09 ppm) (Figures 1A, B and Figure
S2). In addition, the chemical shift ascribed to the methyl group
protons of TK (1.58 ppm) in the mPEG-TK-MPH spectrum can
be observed. The mean molecular weight of mPEG-TK-MPH
and mPEG-MPH prodrugs, obtained by MALDI TOF, were
5374.8 and 5300.7 g/mol, respectively, right-shifted in the
spectra with respect to the MW of their starting polymers:
mPEG-TK-COOH (5233.1 g/mol) and mPEG-P.A. (5168.5 g/
mol). The characterization results confirmed the covalent
conjugation of MPH to both mPEG polymers (mPEG-TK-
COOH and mPEG-PA).
Size and Morphology of Self-Assembled
mPEG-TK-MPH and mPEG-MPH Prodrug
Micelles
Since mPEG-TK-MPH and mPEG-MPH prodrugs have a
hydrophilic portion (mPEG) covalently linked to a
hydrophobic molecule (MPH), they might self-assemble in
aqueous solution. This possibility was investigated by PCS and
AFM. Therefore, a study of size variation and poly-dispersity as a
function of the prodrug aqueous concentration was performed in
milliQ water a range of 0.1–10 mg/ml (Figure 2A). At any
concentration, from 10 to 0.1 mg/ml, the mean size of mPEG-
TK-MPH self-assembly micelles ranged from 260 to 300 nm.
On the contrary, PDI values, indicating the homogeneity of
the samples, varied; under 0.25 mg/ml, both prodrugs formed
assemblies with extremely high PDI values demonstrating a non-May 2020 | Volume 11 | Article 574
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all PDI values were acceptably low. The lowest PDI values
(0.111), indicating the highest sample homogeneity, was
recorded at 0.7 mg/ml.
mPEG-TK-COOH did not show monodisperse compositions
with high PDI values at all concentrations (Figure S3); this was
an expected result considering that due to its non-amphipathic
nature this polymer does not self-assembly. Since mPEG-TK-
MPH suspended at the concentration of 0.7 mg/ml showed the
lowest PDI index, this concentration was selected to further
characterize the morphology of self-assembled prodrugs by
AFM. The analyzed sample of mPEG-TK-MPH suspended atFrontiers in Pharmacology | www.frontiersin.org 70.7 mg/ml demonstrated spherical structures sizing around 100
nm (around 50–80 Ångström) that can be ascribed to prodrug
micelles (Figure 2B).
The discrepancy in size among mean hydrodynamic size and
the mean size obtained by AFM could be related to the fact that
the effective hydrodynamic size includes the solvent surface
layers of nanocarriers, which are no longer present in dried
samples used for high-resolution microscopic techniques
(Oddone et al., 2016). This result is in accordance with other
research works in which particle size measured using PCS
differed from that measured by TEM (Souza et al., 2016; Wang
et al., 2019b).A
B
FIGURE 1 | 1H NMR spectra in CD3CD. (A) mPEG-TK-MPH and (B) mPEG-MPH.May 2020 | Volume 11 | Article 574
Oddone et al. Responsive Polymeric Prodrug Against GlioblastomaCytotoxicity Studies of mPEG-TK-MPH
and mPEG-MPH on Murine GBM Cells (C6)
and Healthy Astrocyte Cells (DI TNC1)
The selectivity of ROS-responsive mPEG-TK-MPH prodrug for
GBM versus healthy cells in vitro was evaluated on rat GBM cells
(C6 cells) and “healthy” primary rat astrocytes cells (DI TNC1).
The levels of ROS produced intrinsically by these cells were
comparatively measured (data not shown), highlighting that C6
cells produced significantly higher levels of ROS than DI TNC1
cells, in agreement with previous studies (Oddone et al., 2019).
Cytotoxicity ofMPH-based prodrugs onC6 andD1 TNC1 cells
were evaluated showing that when C6GBM cells (Figure 3A) were
treated with either mPEG-TK-MPH prodrug or free MPH, a
significant cell growth inhibition in comparison to the control
group was observed (Figure 3A). Furthermore, the cell growth of
C6 cells treatedwithmPEG-TK-MPHwas significantly inhibited in
comparison to that of cells treated with mPEG-MPH. To answer a
question about a possible mechanism which could justify high
cytoxicity of mPEG-TK-MPH with respect to mPEG-MPH, we
stressed that when the level of ROS in endosomes is elevated, a ROSFrontiers in Pharmacology | www.frontiersin.org 8response can induce drug release and endosomal escape (Sun et al.,
2017). As we previously confirmed that Cy5 from mPEG-TK-Cy5
conjugate (which was obtained starting from the same ROS-
responsive polymer, mPEG-TK-COOH) is endocytosed by C6
GBM cells, and then released inside these cells (Oddone et al.,
2019). We therefore imagine that after the endocytosis of self-
assembled mPEG-TK-MPH micelles, the presence of ROS inside
the endosomes can trigger the cleavage of TK bonds from the
prodrugs with subsequent MPH release. Afterward, the released
MPH can escape from the endosomes and then diffuse into the cell
nucleus, where MPH finally will inhibit cell proliferation by
inducing DNA inter-strand cross-links (ICL) (Kühne et al., 2009;
Xiong et al., 2015).
Nevertheless, the cytotoxicity of the free drug was
significantly higher in comparison to either of the prodrugs in
cancer cells (Figure 3A), but also in healthy cells (Figure 3B).
This may be due to a higher cell uptake favored by L-type amino
acid transporters (LATs) (Kühne et al., 2009) (as L-type amino
acid transporter 1, LAT1), which transport neutral amino acids,
including leucine. This transporter is present also in glioma cells,A
B
FIGURE 2 | (A) Mean size and PDI of prodrug micelles at different prodrug concentrations. (B) Representative AFM image and height profile of mPEG-TK-MPH
dispersed in water at a concentration of 0.7 mg/ml.May 2020 | Volume 11 | Article 574
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et al., 2006; Kuczma et al., 2016), and can promote MPH active
transport into cells (Lin et al., 2004). In addition, taking into
consideration its hydrophobic nature, passive transport of the
free form of the drug cannot be excluded (Kühne et al., 2009).
In contraposition, a decreased activity of MPH when in
mPEG-TK-MPH prodrug was experienced, we hypothesized
that these prodrugs are internalized by endocytosis, probably
by fluid-phase endocytosis, as previously observed with mPEG-
Cy5 conjugates (Oddone et al., 2019). As these prodrugs were not
modified with any targeting ligand for GBM cells, their cell
uptake might not be as high as it could be by exploiting receptor-
mediated endocytosis (Zhang et al., 2019). Apart from this
aspect, since TK cleavage was previously confirmed to be
dependent not only on ROS amount but also of the exposed
time to ROS (Oddone et al., 2019), it can be argued that the time
needed to release MPH from the prodrug and/or micelle-like
architecture may impact release kinetics and, therefore increase
or decrease the rate of GBM cell death induction.
Regarding “healthy” DI TNC1 astrocyte cells, the prodrugs
did not influence cell growth (Figure 3B), indicating the inability
of triggering MPH drug release from mPEG-TK-MPH in cells
with physiological levels of ROS, which are lower than in other
glioma (C6) cancer cells (Oddone et al., 2019). On the other
hand, control treatment with free MPH led to a pronouncedFrontiers in Pharmacology | www.frontiersin.org 9inhibition of cell growth in both cell lines. This could be ascribed
to the expression of LAT1 transporters in all cells (Sampaio-Maia
et al., 2001).
At the end of the experiment, concerning prodrugs
administrations, the normalized cell index of free MPH treated
cells was ~245-fold lower in healthy cells, describing a very low
selectivity toward cancer versus healthy cells as described by
several studies, and the frequent side-effects of free MPH (Kühne
et al., 2009; Kuczma et al., 2016). Remarkably, from analysis of
the normalized cell index ratio between mPEG-TK-MPH and
free MPH in both types of cells (Figures 3A, B), we can conclude
that mPEG-TK-MPH was significantly favorable in terms of
safety treated in healthy cells with minimal toxicity and showed
good selectivity in the case of cancer cells, with normalized cell
index ratios at 48 h treatment of (295 vs 1.8, respectively).
In Vitro Studies of mPEG-TK-MPH and
mPEG-MPH Prodrugs on Human GBM
Cells
Apart from performing cytotoxicity studies with the prodrugs on
rat GBM cells, studies were also performed using two human
GBM cell lines: U87 MG and U251 MG, derived from grade IV
GBM tumors. These cell lines are frequently used for in vitro
drug screening previous to in vivo tests in animal models
(Lenting et al., 2017).A
B
FIGURE 3 | Normalized Cell Index curves of C6 (rat GBM cells) and DI TNC1 (Astrocyte cells). Both types of cells were treated with mPEG-TK-COOH (polymer
control), free MPH (11 µM), mPEG-TK-MPH, and mPEG-MPH prodrugs at an equivalent MPH concentration (11 µM) for 48 h. (A) C6 cells. Statistics: One-way
ANOVA tests with Bonferroni post-test. Between the dashed lines is indicated the time period in which the differences between treatments are significant and are
depicted in the graph (***p ≤ 0.001). Time range: 19.5 h from the addition of the treatments, up to the end of the experiment (48 h). (B) DI TNC1. The significant
difference depicted in the graph was calculated considering the full time range from the addition of the different treatments to the end of the experiment (48 h).May 2020 | Volume 11 | Article 574
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indirectly measured by incubating the cells with DHE, a dye that
can detect cytosolic superoxide, peroxynitrite, and hydroxyl
radical (Wojtala et al., 2014). The results indicate a higher level
of ROS in U251 MG in comparison to U87 MG cells (Figure 4).
Next, the cytotoxicity of mPEG-TK-MPH and mPEG-MPH
prodrugs on these human GBM cells was assayed by treating the
cells with different concentrations of free MPH, or either of the
prodrugs (at an equivalent concentration of MPH), or an
equivalent volume of cell media (which was used as control
values and set as 100% for comparison) for 48 h. Regarding U87
MG cells, neither the ROS-responsive mPEG-TK-MPH nor theFrontiers in Pharmacology | www.frontiersin.org 10non-ROS responsive mPEG-MPH prodrugs showed to be
cytotoxic at the MPH concentration range and time used in
this experiment (Figure 5A). On the contrary, at 500 and 1,000
µM equivalent concentrations of MPH, only mPEG-TK-MPH
showed to be cytotoxic on U251 MG cells (Figure 5B) with a
significant reduction on cell viability in comparison to the
control prodrug mPEG-MPH.
As it was observed for rat GBM cells, the cytotoxicity obtained
with free MPH was significantly higher than the observed with
either of the prodrugs (Figures 5A, B), with IC50s of 89 and
16 µM in U87 MG and U251 MG cells, respectively. This result
could be related to the higher sensitivity of these kind of cells toA B
C
FIGURE 5 | Cytotoxicity studies on human GBM cells. (A) U87 MG cells treated with increasing concentration of either free MPH, mPEG-TK-MPH, or mPEG-MPH
prodrugs at equivalent MPH concentrations for 48 h. (B) U251 MG cells treated with increasing concentration of either free MPH, mPEG-TK-MPH, or mPEG-MPH
prodrugs at equivalent MPH concentrations, for 48 h. Statistics: Two-way ANOVA tests with Bonferroni post-test. Comparisons: mPEG-MPH vs. mPEG-TK-MPH
(**p ≤ 0.01 and ***p ≤ 0.001). (C) Co-incubation of U251 MG cells treated with free MPH, mPEG-TK-MPH, or mPEG-MPH prodrugs, with H2O2 (100 µM). Statistics:
Two-way ANOVA tests with Bonferroni post-Comparisons: mPEG-MPH vs. mPEG-TK-MPH and mPEG-TK-MPH + H2O2 (*p ≤ 0.05 and **p ≤ 0.01), mPEG-MPH +
H2O2 vs. mPEG-TK-MPH and mPEG-TK-MPH + H2O2 (
+p ≤ 0.05 and ++p ≤ 0.01), mPEG-MPH or mPEG-TK-MPH (w/and w/o H202) vs. MPH and MPH + H2O2
(•••p ≤ 0.001).A B
FIGURE 4 | ROS levels on human GBM cells. (A) Representative images of U87MG and U251MG cells treated with DHE. (B) Quantification of DHE intensity on
human GBM cells Statistics: Unpaired t-test (*p < 0.05).May 2020 | Volume 11 | Article 574
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responsible for the active transport of MPH into proliferating
tumor cells including U87 MG and U251 MG.
As higher levels of ROS were found in U251 MG in
comparison to U87 MG, we hypothesize that the higher
cytotoxicity of mPEG-TK-MPH in U251 MG might be related
to the higher intrinsic intracellular levels of ROS produced by
these cells.
An alternative explanation for the lower cytotoxicity of
mPEG-TK-MPH in comparison with free MPH might lie on a
possible insufficient TK cleavage by ROS. Therefore, to
investigate if, by increasing the level of ROS, the cytotoxicity of
ROS-responsive mPEG-TK-MPH can be increased, we forced
experimental conditions by adding H2O2 as a ROS enhancer.
We, First, different H2O2 concentration on either of the GBM
cells were tested in order to choose a non-toxic concentration
(Figure S4). A non-toxic H2O2 concentration of 100 µM was
used to measure the intracellular levels of ROS in U87 MG and
U251 MG cells after different H2O2 incubation times (Figure
S5). We observed that the levels of ROS in U87MG cells treated
with H2O2 at different times did not increase (Figure S5A). In
contrast, the levels of ROS in U251 MG cells were particularly
increased after 24 h incubation with H2O2, suggesting that H2O2
can be used to force the release of higher amounts of MPH in
these cells. Therefore, next, we tested the effect of H2O2 on the
cytotoxicity of mPEG-TK-MPH in U251 MG cells. Free MPH,
mPEG-TK-MPH or mPEG-MPH, were co-incubated with 100
µM H2O2 for 48 h. Remarkably, at the equivalent MPH
concentrations tested (500 and 1,000 µM), we observed
(Figure 5C) a more evident cytotoxic effect of mPEG-TK-
MPH corresponding to a slight reduction of cell viability in
H2O2 co-incubated cells, compared to standard cell conditions.
This result, therefore, confirmed that when the intracellular
concentration of ROS increases, the release of MPH from
mPEG-TK-MPH and its cytotoxic activity improve.Evaluation of the Potential Synergistic
Effect of X-Ray Irradiation on Human GBM
Cells Treated With mPEG-TK-MPH and
mPEG-MPH Prodrugs
In U251 human GBM cells, mPEG-TK-MPH showed to be
cytotoxic at concentrations higher than 500 µM. Since an
improved cytotoxicity of mPEG-TK-MPH prodrug after
additional enhancement of ROS using H2O2 was noticed, it
was hypothesized that the physiological levels of ROS in GBM
cells might not be enough to induce TK linker cleavage from the
ROS-responsive prodrug (mPEG-TK-MPH). Radiotherapy,
defined as the use of ionizing radiation (IR) in therapy, was
reported to be able to stimulate and increase mitochondrial-
related ROS (Kawamura et al., 2018). Given that the current
clinical setting used for GBM treatment is based on concomitant
chemotherapy and radiotherapy to improve patient survival
(McKelvey et al., 2018), the effect of combining ROS-Frontiers in Pharmacology | www.frontiersin.org 11responsive prodrug treatment with X-ray, a type of IR, on
human GBM cells was explored.
Notably, only a few studies report ROS-responsive DDS used
in combination with a different type of IR (g-ray). For instance,
ROS-responsive selenium-based micelles containing
doxorubicin demonstrated to have a synergistic antitumor
effect on hepatocellular carcinoma cells at 5 Gy radiation dose
(Ma et al., 2011). This result could be explained due to a higher
sensitivity of hepatocellular carcinoma cells in promoting ROS
induction after irradiation. Similarly, tellurium-based micelles
(Cao et al., 2015) demonstrated to respond to an even lower
radiation dose (2 Gy).
As a consequence, a protocol in which GBM cells received an
overall X-ray dose of 8 Gy at 2 times (4 Gy as an initial dose and 4
Gy after 24 h) was performed, which showed that irradiated U87
MG and U251 MG cells did not suffer from any cytotoxicity
(Figures 6A, B). Then, the cytotoxicity of mPEG-TK-MPH and
mPEG-MPH at 1,000 µM equivalent concentration of MPH
(MPH concentration in which we observed the highest
cytotoxicity of mPEG-TK-MPH on U251 MG cells) on
irradiated human GBM cells was tested. Remarkably, viability
tests showed an increase in cytotoxicity upon prodrug (mPEG-
MPH and mPEG-TK-MPH) treatment and irradiation (Figures
6A, B) in comparison to control cells on both U87 MG and U251
MG cells.
As shown in previous experiments by Gill and Vallis, the
cytotoxic effect obtained by the combination of a
chemotherapeutic drug and IR is higher than predicted due to
the additive effect of the therapies, meaning that the
chemotherapeutic drug can be classified as a radiosensitizer.
Since many potent radiosensitizers are DNA-damaging agents
(Gill and Vallis, 2019), MPH could be reasonably investigated as
radiosensitizer agent by increasing IR cytotoxicity. While for free
MPH there was no difference observed among irradiated and
non-irradiated cells (Figures 6A, B), the high cytotoxicity of free
MPH on any of the cell lines might explained why at the dose
applied in these experiments a synergistic effect was not evident;
however, the higher cytotoxicity seen with mPEG-MPH and
mPEG-TK-MPH on U87 MG and with mPEG-MPH on U251
MG irradiated cells, might be due to a synergistic effect with
MPH acting as a radiosensitizer. The lack of toxicity in U87MG
cells is likely that the ROS status, even in the presence of beam
radiations, does not reach the required amount to cleave TK
group on mPEG-TK-MPH prodrug.
In the case of U251 MG cells, the cytotoxicity of mPEG-TK-
MPH treated, and irradiated cells was significantly higher in
comparison to mPEG-MPH treated and irradiated cells (Figure
6B). Nevertheless, the slight reduction on cell viability of mPEG-
TK-MPH treated and irradiated cells in comparison to only
mPEG-TK-MPH (without irradiation) was not significant. This
result might indicate that at the X-ray dose received, the
production of ROS was not enough strong to induce TK bond
cleavage and MPH release from mPEG-TK-MPH to achieve
higher cytotoxicity.May 2020 | Volume 11 | Article 574
Oddone et al. Responsive Polymeric Prodrug Against GlioblastomaThus, we can conclude that the radiation conditions used
were not capable to produce sufficient concentrations of ROS
that trigger the release of active MPH. Possible instant or
cumulative effect on ROS production could be obtained by
using higher X-ray dose or X-ray dose regimen (e.g.
fractionation, kinetic) respectively. In addition, it could be
interesting to investigate in further experiments alternative IR
therapy such as alpha and beta radiation, that might have a
different impact on ROS production and therefore, on
TK cleavage.
Since the local administration of drugs has been investigated
as it offers the possibility to bypass the BBB and blood brain
tumor barrier (BBTB), concentrating higher amounts of drug in
malignant tumors (Nam et al., 2018), it would be interesting to
provide a locally sensitive strategy which would make it
possible to have synergism with other actions including
radiotherapy for the cleavage and drug activity. For the
moment, pilot clinical studies using intravenous MPH have
not shown any significant impact (Anderson et al., 2015). Thus,
this new activatable ROS-responsive prodrug agent is
interesting for local administration, or alternatively could beFrontiers in Pharmacology | www.frontiersin.org 12further functionalized with a BBB-targeting ligand, such as our
previous work with the g7-peptide, promoting its passage into
the brain for intravenous applications (Cox et al., 2019) and
should be further explored.CONCLUSIONS
With this study, we demonstrated that ROS-sensitive mPEG-
TK-MPH displayed a higher anticancer activity and
cytotoxicity than the non-ROS sensitive prodrug mPEG-MPH
in rat C6 and human U251 MG GBM cells. Furthermore, we
demonstrated a higher safety profile of ROS-sensitive mPEG-
TK-MPH since it did not induce any cytotoxicity in healthy
cells (DI TNC1 astrocyte cells). Therefore, due to their ability to
specifically deliver drugs upon ROS stimulus with increased
effectivity and selectivity for cancer over healthy cells, the
application of TK-technology in the design of prodrugs could
be considered as a promising approach for the development of
future therapeutics against GBM. In addition, we investigated
the potential synergistic activity of X-ray radiation on humanA
B
FIGURE 6 | Influence of X-ray irradiation on human GBM cells treated with mPEG-TK-MPH and mPEG-MPH. (A) U251 MG cells and (B) U87 MG cells. Statistics:
One-way ANOVA tests with Bonferroni post-test. Comparisons: Control vs. mPEG-MPH, mPEG-MPH + 8 Gy, mPEG-TK-MPH and mPEG-TK-MPH + 8Gy (♦p ≤
0.05 and ♦♦♦p ≤ 0.001); mPEG-MPH vs. mPEG-MPH + 8 Gy, mPEG-TK-MPH and mPEG-TK-MPH + 8 Gy (***p ≤ 0.001); mPEG-MPH + 8 Gy vs. 8 Gy, mPEG-TK-
MPH and mPEG-TK-MPH + 8Gy (+p ≤ 0.05 and +++p ≤ 0.001), mPEG-TK-MPH vs. 8 Gy and mPEG-TK-MPH + 8 Gy ($$$p ≤ 0.001); 8Gy vs. mPEG-TK-MPH + 8Gy
(◦◦◦p ≤ 0.001); MPH and MPH + 8 Gy vs. Control and all other treatments (•••p ≤ 0.001).May 2020 | Volume 11 | Article 574
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U87MG cells only when also irradiated. On U251MG cells,
both prodrugs demonstrated to be cytotoxic, but in the case of
mPEG-TK-MPH, the cytotoxicity was comparable to non-
irradiated mPEG-TK-MPH treated cells. Thus, the observed
cytotoxicity effect was probably due to the irradiation
increasing MPH toxicity, but not to an additional cleavage of
TK groups by X-ray generated ROS. Since in this work we could
demonstrate that mPEG-TK-MPH respond to intracellular
ROS in GBM cells, we are planning to investigate in situ the
stimuli or local combinations capable of causing the expected
MPH release and antitumor effect.
Furthermore, since the ROS-response technology of
mPEG-TK-MPH was demonstrated to work in GBM cells
expressing high ROS levels, large improvements in terms of
cytotoxicity could be realistically obtained in clinical
translation. This study could be a starting point for a
rationale design of innovative and tailored ROS-responsive
prodrugs, capable of not only improving drug solubility and
mediating selective ROS-triggered drug release but also to
improve the transport of highly cytotoxic drugs with poor cell
permeation. In addition, other diseases such as those with a
pro-inflammatory component, and neurodegenerative diseases
are featured by high levels of ROS as well and the use of TK-
technology might be translated to these diseases by coupling a
selected drug to the mPEG polymer though a TK linkage.DATA AVAILABILITY STATEMENT
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